Funding Opportunities

National Heart, Lung, and Blood Institute/NIH/DHHS Program Number: 44477

Title: RFA-HL-15-022--Stem Cell-Derived Blood Products for Therapeutic Use (R01)                                                                                                                                                                                   

E-mail: thomasj@nhlbi.nih.gov

 Program URL: http://grants1.nih.gov/grants/guide/rfa-files/RFA-HL-15-022.html

National Heart, Lung, and Blood Institute (NHLBI) invites applications for research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells.

This FOA will use the NIH Research Project (R01) award mechanism.

DEADLINE NOTE

Applications may be submitted to Grants.gov in response to this announcement on or after January 20, 2015. The deadline for receipt of optional letters of intent is January 20, 2015. The deadline for receipt of full applications is February 20, 2015, by 5:00 PM local time of applicant organization.

 National Heart, Lung, and Blood Institute/NIH/DHHS Program Number: 44500

Title: RFA-HL-15-030--Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)                                                                                                                                                       

E-mail: shimian.zou@nih.gov

Program URL: http://grants1.nih.gov/grants/guide/rfa-files/RFA-HL-15-030.html

National Heart, Lung, and Blood Institute (NHLBI) invites applications for Small Business Innovation Research (SBIR) from small business concerns (SBCs) for the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability.  This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications.

DEADLINE NOTE

Applications may be submitted to Grants.gov in response to this announcement on or after January 20, 2015. The deadline for receipt of optional letters of intent is 30 days prior to the application due date. The deadlines for receipt of full applications are: February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only), by 5:00 PM local time of applicant organization.

Directorate for Biological Sciences/NSF Program Number: 00443

Division of Integrative Organismal Systems (IOS)


E-mail: IOSBSC@nsf.gov

Web Site: http://www.grants.gov/view-opportunity.html?oppId=241815

Program URL: http://www.nsf.gov/pubs/2013/nsf13600/nsf13600.htm

The Division of Integrative Organismal Systems (IOS) supports research aimed at understanding why organisms are structured the way they are and function as they do. Proposals should focus on organisms as a fundamental unit of biological organization. Principal Investigators (PIs) are encouraged to apply systems approaches that will lead to conceptual and theoretical insights and predictions about emergent organismal properties. Areas of inquiry include, but are not limited to,
developmental biology and the evolution of developmental processes, nervous system development, structure, and function, physiological processes, functional morphology, symbioses, interactions of organisms with biotic and abiotic environments, and animal behavior.  

Deadline(s): 01/16/2015

DEADLINE NOTE
Preliminary proposals are due by January 16, 2015. Full proposals are due
by August 7, 2015.

BD Biosciences

BD Biosciences Stem Cell Research Grants aim to support the continuing study of embryonic, adult, and induced pluripotent stem cells to improve the understanding of both normal and disease processes.  A total of $100,000 worth of research reagents are awarded annually to 10 scientists. Through the grant program, BD Biosciences supports scientists pursuing innovative ideas in stem cell research, helping to define the next generation of scientific breakthroughs.  The application process is simple.  Just write an abstract (850 words maximum), review and accept the program terms and conditions, complete the online application, and submit.  Summer 2015 award cycle applications are due December 31, 2014.  Click here for more information                                                                 

Differentiation and Integration of Stem Cells (Embryonic and Induced-Pluripotent) Into Developing or Damaged Tissues (R01)

E-mail: mukhopam@mail.nih.gov

National Institute of Child Health and Human Development (NICHD) invites in vivo studies of stem cells in animal models and in humans (if applicable) to better understand how stem cells function within developing or damaged tissues. The areas of emphasis would include systematically profiling and cataloging changes at genetic and epigenetic levels that take place in stem cells and their microenvironment. The purpose is to gain in-depth knowledge of the mechanisms involved in: progressive differentiation of Embryonic Stem Cells (ESCs) into embryonic lineages, progenitor cells and specialized cell types; adult stem cells/progenitor cells during tissue regeneration and wound healing; and Induced Pluripotent Stem Cells (iPSCs) at the site of injury during stem cell therapy.

Understanding the basic mechanisms and application of knowledge-based approaches would allow researchers to generate iPSCs that are more closely related to the ESCs at both genetic and epigenetic levels.

Furthermore, it is expected that replicating developmental mechanisms would ameliorate the safety concerns associated with incomplete differentiation and improper integration of cells in damaged or diseased tissues during stem cell therapy.  This FOA will use the NIH Research Project (R01) award mechanism.  <S2S>  Click here for more details.

Differentiation and Integration of Stem Cells (Embryonic and Induced-Pluripotent) Into Developing or Damaged Tissues (R21)   

E-mail: mukhopam@mail.nih.gov

National Institute of Child Health and Human Development (NICHD) invites in vivo studies of stem cells in animal models and in humans (if applicable) to better understand how stem cells function within developing or damaged tissues. The areas of emphasis would include systematically profiling and cataloging changes at genetic and epigenetic levels that take place in stem cells and their microenvironment. The purpose is to gain in-depth knowledge of the mechanisms involved in: progressive differentiation of Embryonic Stem Cells (ESCs) into embryonic lineages, progenitor cells and specialized cell types; adult stem cells/progenitor cells during tissue regeneration and wound healing; and Induced Pluripotent Stem Cells (iPSCs) at the site of injury during stem cell therapy. Understanding the basic mechanisms and application of knowledge-based approaches would allow researchers to generate iPSCs that are more closely related to the ESCs at both genetic and epigenetic levels. Furthermore, it is expected that replicating developmental mechanisms would ameliorate the safety concerns associated with incomplete differentiation and improper integration of cells in damaged or diseased tissues during stem cell therapy.  This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.  <S2S>  Click here for more details.

Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R01)        

E-mail: oleg.mirochnitchenko@nih.gov

 The sponsors invite applications aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.  The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.  This FOA will use the NIH Research Project (R01) award mechanism.  The deadlines for receipt of standard applications under this announcement are: February 5, June 5, and October 5 annually.  This program will expire on May 8, 2016.  Click here for more details.

Improvement of Animal Models for Stem Cell-Based Regenerative Medicine (R21)

 E-mail: oleg.mirochnitchenko@nih.gov                    

The sponsors invite applications aimed at characterizing animal stem cells and improving existing, and creating new, animal models for human disease conditions.  The intent of this initiative is to facilitate the use of stem cell-based therapies for regenerative medicine. The initiative focuses on the following areas: 1) comparative analysis of animal and human stem cells to provide information for selection of the most predictive and informative model systems; 2) development of new technologies for stem cell characterization and transplantation; and 3) improvement of animal disease models for stem cell-based therapeutic applications.  This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism.  The deadlines for receipt of standard applications under this announcement are: February 16, June 16, and October 16 annually.  This program will expire on May 8, 2016.  Click here for more details.

Institute for Regenerative Medicine

2012 Pilot Project Program (closed)
The Penn Institute for Regenerative Medicine (IRM) is pleased to announce a call for pilot project proposals in the areas of stem cell research and regenerative medicine.  These proposals must focus on the pursuit of new ideas and technologies that would result in innovations transforming these fields.  The IRM will fund at least four (4) applications beginning in April 1, 2012.  Deadline is February 29, 2012.  Click here for more details.